Key Points
- OraSure Technologies director Steven Kyle Boyd bought 25,000 shares on May 12 at an average price of $2.98, a transaction worth $74,500 that increased his ownership by 65%.
- Bdoy also made another purchase of 25,000 shares on May 14 at $2.99 per share, signaling continued insider buying in the stock.
- OSUR shares were down 3% to $2.95, while Wall Street currently has a Reduce consensus rating and an average price target of $3.00.
OraSure Technologies, Inc. (NASDAQ:OSUR - Get Free Report) Director Steven Kyle Boyd purchased 25,000 shares of the firm's stock in a transaction dated Tuesday, May 12th. The shares were bought at an average price of $2.98 per share, with a total value of $74,500.00. Following the purchase, the director owned 63,462 shares in the company, valued at $189,116.76. The trade was a 65.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Steven Kyle Boyd also recently made the following trade(s):
- On Thursday, May 14th, Steven Kyle Boyd acquired 25,000 shares of OraSure Technologies stock. The stock was purchased at an average price of $2.99 per share, for a total transaction of $74,750.00.
OraSure Technologies Trading Down 3.0%
Shares of NASDAQ OSUR opened at $2.95 on Friday. The stock has a fifty day simple moving average of $3.06 and a two-hundred day simple moving average of $2.76. OraSure Technologies, Inc. has a 1-year low of $2.08 and a 1-year high of $3.82. The firm has a market cap of $203.11 million, a price-to-earnings ratio of -2.84 and a beta of 0.89.
OraSure Technologies (NASDAQ:OSUR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 25th. The medical instruments supplier reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.02). The firm had revenue of $26.76 million for the quarter, compared to analysts' expectations of $26.44 million. OraSure Technologies had a negative net margin of 66.42% and a negative return on equity of 18.57%.
Wall Street Analyst Weigh In
Separately, Weiss Ratings upgraded shares of OraSure Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, May 7th. Two research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, OraSure Technologies presently has a consensus rating of "Reduce" and an average target price of $3.00.
Read Our Latest Research Report on OSUR
Institutional Trading of OraSure Technologies
A number of institutional investors have recently added to or reduced their stakes in OSUR. Altai Capital Management L.P. boosted its stake in OraSure Technologies by 73.4% in the 3rd quarter. Altai Capital Management L.P. now owns 3,748,836 shares of the medical instruments supplier's stock worth $12,034,000 after purchasing an additional 1,586,488 shares during the period. Millennium Management LLC increased its position in shares of OraSure Technologies by 71.1% during the third quarter. Millennium Management LLC now owns 2,112,507 shares of the medical instruments supplier's stock valued at $6,781,000 after buying an additional 878,151 shares during the period. Cannell Capital LLC lifted its holdings in shares of OraSure Technologies by 12.6% in the third quarter. Cannell Capital LLC now owns 2,099,815 shares of the medical instruments supplier's stock worth $6,740,000 after buying an additional 234,826 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of OraSure Technologies by 6.4% in the second quarter. Geode Capital Management LLC now owns 1,869,868 shares of the medical instruments supplier's stock worth $5,611,000 after buying an additional 112,851 shares in the last quarter. Finally, Kotler Kevin bought a new position in shares of OraSure Technologies in the fourth quarter valued at approximately $4,359,000. Hedge funds and other institutional investors own 93.50% of the company's stock.
About OraSure Technologies
(
Get Free Report)
OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.
The company's flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
